EMERYVILLE, Calif.,
June 9, 2021 /PRNewswire/
-- Dynavax Technologies Corporation (Nasdaq: DVAX), a
biopharmaceutical company focused on developing and commercializing
novel vaccines, today announced that Ryan
Spencer, Chief Executive Officer, will present virtually at
the Goldman Sachs 42nd Annual Global Healthcare Conference on
Thursday, June 10, 2021 at
3:50 p.m. E.T.
The presentation will be webcast and may be accessed through the
"Events & Presentations" page on the "Investors" section of the
Company's website at
http://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial stage
biopharmaceutical company developing and commercializing novel
vaccines. The Company's first commercial product, HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the
U.S. and the European Union for prevention of infection caused by
all known subtypes of hepatitis B virus in adults age 18 years and
older. Dynavax is also advancing CpG 1018 adjuvant as a premier
vaccine adjuvant through research collaborations and partnerships.
Current collaborations are focused on adjuvanted vaccines for
COVID-19, pertussis and universal influenza. For more information,
visit www.dynavax.com and follow the company on LinkedIn.
Contacts:
Nicole
Arndt
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-301309437.html
SOURCE Dynavax Technologies